Format

Send to

Choose Destination
See comment in PubMed Commons below
Liver Transpl. 2005 Nov;(11 Suppl 2):S57-62.

Recurrence of hepatitis C infection: Where are we now?

Author information

1
Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. charlton.michael@mayo.edu

Abstract

1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving. (

PMID:
16237717
DOI:
10.1002/lt.20597
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center